logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12357712 B1

PDFFull Text
Date of Patent:
Jul. 15, 2025

Filed:

May. 22, 2020

Targeted radiopharmaceutical for tumor and its use in the imaging-guided combination therapy of targeted radiotherapy and immunotherapy

Applicant:

Beijing Giluntide Pharmaceutical Co., Ltd., Beijing, CN;

Inventors:

Fan Wang, Beijing, CN;

Jiyun Shi, Beijing, CN;

Hannan Gao, Beijing, CN;

Bing Jia, Beijing, CN;

Assignees:

Beijing Giluntide Pharmaceutical Co., Ltd., Beijing, CN;

Peking University, Beijing, CN;

Attorney:

McCarter & English, LLP

Primary Examiner:

Michael G Hartley

Assistant Examiner:

Kaila A Craig

Int. Cl.
CPC ...
A61K 51/08 (2006.01); A61P 35/00 (2006.01); C07B 59/00 (2006.01); C07K 7/64 (2006.01);
U.S. Cl.
CPC ...
A61K 51/082 (2013.01); A61K 51/088 (2013.01); A61P 35/00 (2018.01); C07B 59/004 (2013.01); C07K 7/64 (2013.01);
Abstract

A pharmacological composition contains a complex having a structurally modified RGD polypeptide a radionuclide. This pharmacological composition is useful for diagnosis or treatment of the integrin αvβ3-positive tumors. The pharmacological composition may further contain an immunotherapeutic medicament and an optional nanoantibody molecular imaging probe. Treatment with a PD-L1 blockade after the targeted radioactive therapy can archive the optimal synergic efficacy. Moreover, with administration of PD-1 or PD-L1 nanoantibody molecular imaging probe, expression of PD-1 or PD-L1 in the tumor after targeted radiotherapy can be observed.

Find Patent Forward Citations

Wang, Fan. (2025). Targeted radiopharmaceutical for tumor and its use in the imaging-guided combination therapy of targeted radiotherapy and immunotherapy (U.S. Patent No. 12357712). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12357712

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…